Comparing Shattuck Labs (NASDAQ:STTK) and Gain Therapeutics (NASDAQ:GANX)

Shattuck Labs (NASDAQ:STTK) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Volatility & Risk

Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

Profitability

This table compares Shattuck Labs and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Gain Therapeutics	N/A	-161.59%	-118.36%

Insider & Institutional Ownership

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Shattuck Labs and Gain Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1.00 million	550.98	-$48.81 million	($0.51)	-10.76
Gain Therapeutics	$50,000.00	1,230.65	-$20.16 million	($0.50)	-2.82

Gain Therapeutics has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Shattuck Labs and Gain Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	10	2	3.00
Gain Therapeutics	1	0	4	0	2.60

Shattuck Labs currently has a consensus target price of $13.70, suggesting a potential upside of 149.54%. Gain Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 443.74%. Given Gain Therapeutics’ higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Shattuck Labs.

Summary

Shattuck Labs beats Gain Therapeutics on 9 of the 14 factors compared between the two stocks.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.